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Abstract: The intestinal flora has long been thought to play a role either in initiating or in exacerbating the 
inflammatory bowel diseases (IBD). Host defenses, such as those mediated by the Toll-like receptors (TLR), are 
critical to the host/pathogen interaction and have been implicated in IBD pathophysiology. To explore the 
association of genetic variation in TLR pathways with susceptibility to IBD, we performed a replication study 
and pooled analyses of the putative IBD risk alleles in NFKB1 and TLR4, and we performed a haplotype-based 
screen for association to IBD in the TLR genes and a selection of their adaptor and signaling molecules. Our 
genotyping of 1539 cases of IBD and pooled analysis of 4805 cases of IBD validates the published association of 
a TLR4 allele with risk of IBD (odds ratio (OR): 1.30, 95% confidence interval (CI): 1.15-1.48; P= 0.00017) and 
Crohn's disease (OR: 1.33, 95% CI: 1.16-1.54; P= 0.000035) but not ulcerative colitis. We also describe novel 
suggestive evidence that TIRAP (OR: 1.16, 95% CI: 1.04-1.30; P= 0.007) has a modest effect on risk of IBD. 
Our analysis, therefore, offers additional evidence that the TLR4 pathway - in this case, TLR4 and its signaling 
molecule TIRAP - plays a role in susceptibility to IBD.  
Keywords: Toll-like receptor; inflammatory bowel disease; NFKB1; TLR4; TIRAP 
 
Introduction 
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are two chronic 
inflammatory conditions that predominantly affect the gastrointestinal tract. These classifications are important 
for the clinical management of the disease. However, in reality, there are certain cases that either overlap both 
categories or fit in neither, suggesting the existence of a spectrum of diseases collected under the IBD rubric. In 
addition, epidemiologic studies have revealed that relatives of a patient with UC or CD have a higher risk of 
developing either form of IBD.1-3 This suggests that UC and CD share certain genetic susceptibility loci and that 
the ultimate phenotypic expression of the disease also probably depends on other factors such as genetic 
modifier loci and environmental influences. 
One important environmental contribution comes from the bacteria that reside in the gastrointestinal tract. 
Endogenous and pathogenic bacteria and mycobacteria have long been suspected of playing a role in IBD, but 
their involvement in initiating or exacerbating IBD has not been definitively demonstrated in humans.4 Strong 
support for this hypothesis, however, comes from murine model systems in which susceptible mice kept in 
germfree conditions do not develop spontaneous colitis.5 Furthermore, genetic studies in humans and mice have 
made a convincing link between the innate immune system and chronic inflammation. Specifically, studies have 
demonstrated that genetic variants in the host's pattern recognition receptors (PRR) can lead to increased 
susceptibility to colitis. PRRs are molecules of different families, such as the CARD/NOD molecules and Toll-
like receptors (TLR), that recognize microbial products and initiate inflammatory responses as part of the innate 
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immune response to pathogens. An allele of murine TLR4, Lpsd, was first noted to decrease the severity of 
experimental colitis induced by dextran sulfate sodium (DSS),6 and more recently, TLR4-/- and MyD88-/- mice 
have been shown to have more severe DSS-induced colitis than their wild-type littermates.7-9 In addition, 
mutations in CARD15/NOD2 have been associated with susceptibility to human CD10-12 and shown to affect 
nuclear factor-κB (NF-κB) activation, interleukin (IL)-1β processing, and resistance to intestinal Listeria 
monocytogenes infection in mice.13-14 
Within the TLR family of PRR, there are 10 different transmembrane receptors (TLR1-10) that are found either 
on the extracellular surface of cells (TLR1, 2 and 4) or within intracellular compartments such as endosomes 
(TLR3 and 7-9).15 An eleventh TLR sequence (TLR11) was described after the initiation of this project and was 
therefore not assessed in our study; it is still unclear whether TLR11 produces a functional protein in humans.16 
The function of the TLR genes and their associated signaling mechanisms has been characterized in great detail 
in recent years, particularly in the mammalian bowel. In mammals, the intestinal epithelium is a major barrier to 
the entry of microbes into the organism. It is therefore not surprising that the TLR molecules and elements of 
their signaling machinery are expressed not only by resident ileal and colonic macrophages but also by 
components of the intestinal epithelium.17-19 Furthermore, these expression patterns are altered in the context of 
CD or UC and in the presence of an inflammatory mediator.20-23 This evidence, coupled with the observation that 
MYD88 and TLR4 alleles affected the severity of experimental colitis in the mouse, led us to initiate an 
assessment of genetic variation within the TLR pathway for association with human IBD. 
A total of 23 genes implicated in TLR signaling pathways at the project's initiation in 2002 were selected for 
study. These genes include the 10 TLR genes as well as genes whose products interact with the TLR directly at 
the cell surface (MD-2) or intracellularly (MYD88, TIRAP and TOLLIP), and certain genes (IRAKI, IRAK2, 
MAP3-K7IP2/TAB2 and TRAF6) whose products link the latter adaptor proteins to signaling cascades that 
activate the NF-κB pathway (IKKA/CHUK, IKBKB, IKbKG, MAP3K14/NIK and NFKB1).15 At the study's 
initiation, two of the selected genes, NFKB1 and TLR4, were reported to have each one allele associated with 
susceptibility to either CD or UC.24,25 In the first part of our study, we have therefore performed a replication 
study of these two alleles (NFKBl94delATTG and TLR4299Gly) and extended the analysis to include all published 
data on these alleles, as individual replication studies have provided inconsistent results.26-35 Combining the 
results in this fashion provides the necessary statistical power to evaluate genetic risk factors of modest effect, 
such as those observed for multigenic diseases.36 
In the second part of the study, we screened all 23 genes for association with susceptibility to IBD. Current 
collections of IBD samples are not large enough to adequately investigate rare alleles that may contribute to risk 
of IBD. We therefore focused our study on the assessment of common (frequency >0.10) alleles in these genes. 
The initial screen of the TLR pathway was performed using two sample collections from Canada, and results 
from this screen were then followed by a powerful replication study in three additional sample collections. This 
validation effort identified an allele in TIRAP as having evidence for contributing to the risk of developing IBD. 
In addition, the pooled analyses including published data demonstrate that TLR4 but not NFKB1 has one allele 
that is associated with susceptibility to IBD and to its CD subset. 
Results 
Confirming known associations to CD or UC susceptibility  
We first set out to confirm the published associations of , susceptibility to CD or UC with NFKB1 and TLR4 
alleles. Specifically, we attempted to replicate the putative association of the -94delATTG allele of NFKB1 
(NFKB1 94delATTG) with UC and the 299Gly allele of TLR4 (TLR4299G1y) with CD and UC.24,25 We therefore 
genotyped these two putative risk alleles in the nearly 2500 study subjects (Table 1; IBD-1 to -5) for the 
replication analysis, and then we combined these data with those contained in all published reports of association 
in IBD, CD or UC using a Mantel-Haenszel pooled analysis approach. 
For evaluation of the TLR4299Gly allele, the data available was extensive: 4805 IBD subjects of mostly European 
origin from 14 different sample collections (Table 2) have been genotyped and showed no significant evidence 
of genetic heterogeneity (Pearson χ2 goodness-of-fit test, P = 0.055). While the results from the typing of our 
own samples do not provide significant evidence of association with CD, UC or IBD (Table 2), it is not 
inconsistent with such an effect. In fact, the pooled analyses of these results with all of the published replication 
studies (Table 2), excluding the original study to examine an independent effect, demonstrates that there is a 
significant association between TLR4299Gly and the risk of IBD (odds ratio (OR) = 1.22, 95% confidence interval 
(CI): 1.06-1.40; P = 0.002) and confirms the original study. While the original published study estimated a 
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relatively strong genetic effect (OR = 2.34) for this allele, combining all of the current results with the original 
results provide a more accurate estimate of genetic effect (Tables 3 and 4), one which is more modest (OR = 
1.26, 95% CI: 1.10-1.43) although quite significant (P = 0.00017). This association is also found for the CD 
subgroup of IBD (OR = 1.33, 95% CI: 1.16-1.54; P = 0.000035), but there is no statistically significant evidence 
of association for the UC subgroup (P = 0.058). In terms of the putative NFKB1 94delATTG risk allele, Karban et 
al.25 first reported an association with risk of developing UC. We therefore tested this specific hypothesis in our 
entire set of samples but did not find significant evidence of association (OR = 0.99, 95% CI: 0.81-1.2; 
Supplementary Table 2). However, combining these results with previously published replication studies 
(Supplementary Table 2) in a pooled analysis provided modest evidence of association between risk of UC and 
NFKB1 94delATTG (OR = l.12, 95% CI: 1.01-1.23, P = 0.012). There was no evidence of association when the 
allele was analyzed in CD and all IBD samples (data not shown). 
Table 1: Subject samples examined as part of the TLR pathway screen in IBD 
Numbers of affected subjects  
IBD CD UC  Control 
Screening samples    
IBD-1: Canadian triosa 160 135 25 N/Ab 
IBD-2: Canadian C/Cc 114 114 0 68 
Total screening 274 249 25 68 
Replication samples    
IBD-3: Belgian C/C 608 449 148 479 
IBD-4: Belgian trios 104 83 21 N/A 
IBD-5: NIDDK trios (Canada and USA) 933 593 304 N/A 
Total replication 1645 1125 473 479 
Abbreviations:  CD,  Crohn's  disease;  IBD,  inflammatory bowel diseases; NIDDK, National Institute of Diabetes and Digestive and 
Kidney; TLR, Toll-like receptors; UC, ulcerative colitis. 
aTrios, a patient with IBD and both parents. 
bN/A, not applicable given that these are mother-father-affected child trios. 
cC/C, case-control. 
 
IBD susceptibility gene discovery in the TLR pathway 
 In the second part of our study we conducted a screen of the common genetic variation in 23 genes involved in 
TLR signaling pathways for association to IBD. These genes included the 10 genes encoding the TLRs (TLR1-
10), eight of their adaptor proteins, and five molecules involved in the control of the NFKB1 signaling cascade. 
This study was initiated before the data from the International HapMap project was available, and therefore our 
study design consisted of (1) a validation step in which we genotyped 379 single nucleotide polymorphisms 
(SNPs) selected from these 23 genes in 86 trios to determine the linkage disequilibrium (LD) patterns 
surrounding each of the candidate genes, (2) using the LD information for the selection of 115 SNPs that tag the 
common variation in these genes, (3) an association screen where the tag SNPs were typed in 274 Canadian IBD 
samples and their family- and population-based controls samples (Table 1, IBD-1 and -2), and (4) a replication 
study where we typed the SNPs having suggestive or significant evidence of association in the screen, in 1645 
cases and their controls from Belgium, Canada and the United States (Table 1, IBD-3 to -5). 
Specifically following the typing of the 115 SNPs in the screening set of samples, we determined that there was 
no significant genetic heterogeneity between the two sample collections that make up the screening set (data not 
shown), and therefore the results from these cohorts were combined to provide maximal statistical power. These 
analyses identified a single non-coding SNP in TIRAP and four haplotypes in IRAK2, TLR3 and TLR4 as 
having suggestive evidence (P<0.05) of association to IBD (Table 3). These putative associations were then 
tested in the replication sample set of 1645 cases of IBD and their controls. Again there was no significant 
evidence of heterogeneity between the different sample collections that constitute the replication cohort, and 
therefore we performed a combined analysis of cohorts IBD-3 to -5. This analysis revealed that only the TIRAP 
SNP (rs671492) had an association (P = 0.032) that suggested replication of the initial observation of increased 
susceptibility to IBD in subjects carrying the 'G' allele. Specifically the minor 'G' allele of rs671492 (rs671492G) 
has an OR of 1.13 (95% CI: 1.01-1.28; P = 0.032) for susceptibility to IBD in the replication samples; while this 
statistical evidence is suggestive of replication, it falls above a formal threshold of significance (P<0.01) once 
we correct for the five hypotheses tested in the replication phase of the study. Nonetheless, these data present an 
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attractive hypothesis to be pursued further, and, to obtain a more accurate estimate of the magnitude of the effect 
of rs671492G on risk of IBD, we pooled the screening and replication data and estimated that the rs671492G 
allele has a true but modest effect on risk to IBD (OR = 1.16, 95% CI: 1.04-1.30). Since the CD and UC 
subgroups of IBD have distinct genetic associations, we partitioned the pooled stages 1 and 2 data along these 
phenotypic categories and conducted separate analyses on each phenotypic subgroup. Subjects (1374) with CD 
(collections IBD-1 to -5) were used in this secondary analysis of the rs671492G allele (OR = 1.10, 95% CI: 0.97-
1.24); on the other hand, the smaller subgroup of 452 subjects with UC (collections IBD-3 and -5) revealed an 
OR of 1.38 (95% CI: 1.12-1.71) for the rs671492G allele. The IBD-1 and -4 collections were not used in the 
latter analysis given the small number of UC cases that they contain. 
Discussion 
Previous studies of animal models of IBD as well as the discovery of IBD susceptibility alleles in the human 
CARD15 gene have indicated that the innate immune response in patients who develop IBD may be abnormal. 
We were therefore interested in determining whether additional genetic variants in key innate immunity genes 
alter an individual's risk for developing IBD. Thus we chose to perform an association study targeting the TLR 
genes, as well as genes encoding their adaptor molecules and their downstream signaling and regulatory 
molecules. The first step was to determine whether two putative risk alleles (TLR4299G1y in CD and IBD;  
NFKB1-94delAATG in UC) that had previously been reported in the literature could be confirmed. The second step 
was to perform a haplotype-based evaluation of a large number of candidate genes in the same biological 
pathway that had not been thoroughly examined for association to IBD. 
Table 2: Pooled analysis of studies exploring the role of TLR4299Gly in IBD 
Sample Total number of cases  Odds ratio (95% CI)  
  IBD CD UC 
Original observation 
1. Belgian C/C #124 610 2.27 (1.29-4.00) 2.34 (1.32-4.18) 2.05 (1.07-3.93) 
Published replication studies 
2. Belgian trios #124 318 1.68 (1.13-2.52) 1.79 (1.14-2.82) None 
3. Dutch C/C #133 112 2.05 (1.08-3.89) 2.05 (1.08-3.89) None 
4. Dutch C/C #232 591 1.44 (0.92-2.25) 1.51 (0.94-2.44) 1.30 (0.73-2.34) 
5. German C/C #134 200 2.08 (1.19-3.98) 1.71 (0.77-3.77) 2.34 (1.10-1.98) 
6. German C/C #228 204 1.95 (1.03-3.70) 1.95 (1.03-3.70) None 
7. Greek C/C29 205 2.10 (0.85-5.20) 2.78 (1.09-7.10) 1.18 (0.37-3.74) 
8. Hungarian C/C30 527 0.81 (0.50-1.32) 0.81 (0.50-1.32) None 
9. Scottish C/C26 499 0.99 (0.60-2.07) 1.20 (0.76-1.90) 0.77 (0.47-1.27) 
Novel replication studies performed as part of our TLR screen 
10. Canadian trios 160 1.00 (0.57-1.74) 1.00 (0.56-1.78) Not included 
11. Canadian C/C 114 0.86 (0.32-2.27) 0.86 (0.32-2.27) None 
12. Belgian C/C #2 249 1.11 (0.65-2.07) 1.39 (0.99-1.95) 1.09 (0.66-1.80) 
13. Belgian trios #2 104 1.00 (0.57-1.74) 0.89 (0.34-2.30) Not included 
14. NIDDK trios 912 1.02 (0.77-1.35) 1.00 (0.71-1.41) 1.03 (0.64-1.66) 
Summary statistics (OR and 95% CI) 
Novel replication (10-14) 1539 1.04 (0.85-1.26) 1.12 (0.92-1.36) 1.04 (0.82-1.31) 
Replication only (2-14) 4195 1.22 (1.06-1.40) 1.27 (1.10-1.47) 1.08 (0.91-1.28) 
All studies (1-14) 4805 1.26 (1.10-1.43) 1.33 (1.16-1.54) 1.14 (0.97-1.34) 
Summary statistics (P-value) 
Novel replication (10-14) 1539 0.21 0.27 0.38 
Replication only (2-14) 4195 0.0020 0.00064 0.20 
All studies (1-14) 4805 0.00017 0.000035 0.058 
Abbreviations: CD, Crohn's disease; CI, confidence interval; IBD, inflammatory bowel diseases; NIDDK, National Institute of Diabetes and Digestive 
and Kidney; UC, ulcerative colitis. 
A Pearson χ2 goodness-of-fit test reveals no significant evidence of genetic heterogeneity among the 14 sample collection (P = 0.055). 'None' is used 
when collections reported no data on UC samples. 'Not included' is used when collections had too few UC samples to make a meaningful contribution 
to the UC only analysis. They were therefore not considered as part of the pooled analysis. For the two Belgian sample collections (12 and 13) used in 
our replication effort, only samples not previously analyzed in collections 1 and 2 were included in the replication analysis; thus, we excluded 359 
subjects with IBD from collection #12 in this pooled analysis. All of the subjects in collection #13 are new and were therefore all included. For further 
details regarding the subjects included in each study, please see Supplementary Table 1. 
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In an attempt to confirm the published associations of TLR4 and NFKB1 genes with IBD, we typed a large 
number of samples for these variants and also pooled these results with all published replication studies. In doing 
so, we have found evidence to confirm the association of TLR4299G1y with CD and IBD as well as the association 
of NFKB1-94delATTG with UC. It should be highlighted that not all of the individual studies of the TLR4 and 
NFKB1 variants had significant evidence of association, despite the fact that the pooled analyses demonstrated 
significant association (Table 2). These seemingly contradictory results are consistent with the known challenges 
of replication studies: (1) the modest effect size of an allele on disease risk, (2) the modest number of subjects 
involved in both initial and replication studies, (3) the non-homogeneous inclusion and exclusion diagnostic 
criteria for complex diseases across studies, and (4) population-specific or -enriched effects, such as the 
difference in risk allele frequency, in different populations. The latter problem is of particular concern in pooled 
analyses, and we have therefore used a Pearson χ2 goodness-of-fit test to demonstrate that there are no significant 
differences  in allele frequencies of NFKB1-94delATTG or TLR4299Gly in the various sample collections considered 
in the pooled analyses. The pooled analyses therefore represent statistically robust assessments that provide a 
more accurate evaluation of the role of these alleles in risk of disease given the much larger combined sample 
size of the pooled analyses. Lohmueller et al.36 systematically evaluated this approach and demonstrated that 
such pooled analyses offered convincing evidence of replication for 8 out of 25 (32%) of associations that had a 
history of inconsistent replication results in 301 publications. This evaluation was consistent with that Ioannidis 
et al.,37 who used a slightly different approach. The pooled analyses provided herein, therefore, provide 
statistically significant evidence that the TLR4299G1y allele is a true risk factor for CD and IBD; on the other 
hand, we provide more modest evidence that NFKB1-94delATTG is a risk allele for UC. 





















   SNPsHaplotypes      
IKKA 10q24.31 15.0 2 1 None     
IKKB 8pll.21 42.3 2 1 None     
IRAK2 3p25.3 121.1 20 11 H.B.1: GAa 48:31 13.1 16.4 0.042 
     H.B.2: GTAa 33:16 13.2 16.8 0.017 
LY96 8q21.11 353.6 5 None None     
MAP3K1417 q21.31 38.1 4 5 None     
NFkBl 4q24 209.2 10 3 None     
TIRAP llq24.2 26.7 4 5 Rs671492-G 67:39 82.8 81.7 0.033 
TLR1 4pl4 20.0 6 3 None     
TLR2 4q31.3 42.3 5 4 None     
TLR3 4q35.1 8.6 4 5 H.B.1: CTa 40:49 26.2 15.3 0.037 
TLR4 9q33.1 71.1 13 3 H.B.1: GCCa 79:70 17.4 30.6 0.045 
TLR5 1q41-q42 55.8 11 7 None     
TLR6 4pl4 0.16 2 None None     
TLR9 3p21.2 9.4 3 2 None     
TLR10 4pl4 15.9 7 2 None     
TOLLIP 11pl5.5 67.3 10 3 None     
TRAF6 11pl2 46.7 7 4 None     
Abbreviations: IBD, inflammatory bowel diseases; SNP, single nucleotide polymorphism; TDT, transmission disequilibrium test; TLR, 
Tolllike receptors. 
This table summarizes the results of our analysis of 115 tag SNPs in 17 genes involved in TLR signaling. Only those results meeting our 
criteria for replication are listed in this table. The total number of hypotheses tested (both SNPs and haplotypes) is noted at the bottom of the 
table. As noted in out Materials and methods section, only those haplotypes with a frequency >0.l were tested in this analysis. In the third 
column from the right, we report the transmitted:untransmitted (T:U) ratio in our TDT analysis of sample IBD-1. 
aThe haplotypes passing our screening criteria are composed of the following alleles: (1) IRAK 2 haplotype block 1 (H.B.1) - rs779805c and 
rs458952A; (2) IRAK2 H.B.2 - rs708030G, rs2306696T and rs1177614A; (3) TLR3 H.B.1 - G9862a1c and rsl519312T; TLR4 H.B.1 - 
rsl252041G, rs2770150c and rsl927911c. 
 
Given the significant genetic evidence implicating TLR4299Gly in disease risk, it is important to examine how this 
allele may influence biological function and disease pathogenesis. Interestingly, it has been reported that the 
TLR4299Gly variant leads to decreased airway responsiveness to inhaled LPS, decreased NFKB1 activation and 
decreased in vitro IL1α expression in airway epithelial cells.38 However, several other groups report no 
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significant evidence for a functional difference in ex vivo or in vitro characterization of cytokine expression by 
peripheral blood mononuclear cells between subjects having either the Asp or Gly allele at position 299.39-45 It 
should be noted, however, that binding of the TLR4 receptor leads to more than just the activation of NFkB. For 
example, signaling via TLR4 can also lead to the activation of the STAT family of proteins and the triggering of 
gene expression of the IRF family of proteins46 - raising the possibility that TLR4299Gly may affect the function of 
TLR4 signaling by another mechanism. Alternatively, since TLR4 is found within a large block of LD (Figure 
1), the TLR4299Gly allele may simply be highly correlated with the causal allele. In fact, at least one other non-
synonymous coding polymorphism, TLR4Thr399 was found to be on the same haplotype as TLR4299Gly The strong 
correlation between these two coding polymorphisms (r2>0.9 in our data) makes it difficult to resolve their 
genetic effects. The OR associated with each variant are virtually identical, and a previous study indicates that 
both alleles appear to have an effect on NFKB1 activation and IL1α expression.38 
These findings are supported by recent evidence that both TLR4299Gly and TLR4399Ile demonstrate decreased 
responsiveness to LPS and other TLR4 ligands in an in vitro reconstituted TLR4 signaling apparatus when 
compared to the TLR4 proteins bearing the major allele of each SNP (TLR4ASP299 and TLR4Thr399).47 A construct 
containing both minor alleles had a significantly lower response to TLR4 stimulation than all other constructs, 
and all of these differences in responses were noted to be dependent on the stochiometry of TLR4, MD-2 and 
CD14. Thus, we have several clues that could implicate either or the combination of both minor alleles as being 
causal for susceptibility to IBD, but additional work is required to reconcile the results of these in vitro and ex 
vivo experiments and to confirm that no other polymorphism in this large TLR4 haplotype contributes to the 
susceptibility phenotype. 
The second part of our study consisted of a broad screen of the TLR pathway for association with susceptibility 
to IBD, followed by a replication study in an independent set of samples. Using this approach, we identified a 
genetic variant in the gene encoding TIRAP that may be associated with IBD, although its genetic effect is quite 
modest (OR = 1.15). Secondary analyses suggest that this allele may play a more important role in UC (OR = 
1.38) than in CD (OR=1.10). However, the evidence that we present does not meet a threshold of genome-wide 
statistical significance (P<10 8); even within the confines of our study, this result is not formally significant 
when one takes into account the multiple hypotheses being tested. This is not surprising given the very modest 
OR of this putative risk allele in TIRAP, and several thousand more cases of IBD from other collections will 
need to be investigated before we can come to a firm conclusion on the role of this allele in IBD. For now, we 
present our own data as being suggestive of replication for the association of TIRAP with IBD susceptibility 
since the P-value in the replication stage of this study was 0.032, which is just above the 0.01 Bonferroni-
corrected level of significance for the five hypotheses tested in our replication effort. It is intriguing to note that 
the TIRAP gene encodes a protein with a critical role as an adaptor molecule at the juncture of several signaling 
pathways, including that of TLR4. The association that we detect with TIRAP and IBD further suggests that the 
TLR4 pathway plays an important role in IBD pathogenesis. 
It is interesting to note that the genetic associations reported herein only have a modest influence on a person's 
risk to developing IBD (OR = 1.1-1.3) for the NFKB1, TLR4 and TIRAP variants. These genetic effects are in 
the same range as that observed for CTLA4risk in type I diabetes (OR ~1.18)48 and are typical of many other 
chronic inflammatory and autoimmune disease risk alleles.49 We can speculate that these common alleles with 
modest effects on gene function are tolerated in the innate immune system and can provide diversity in a 
population's response to the microbial flora, whereas alleles with stronger effects on function may only be able to 
survive as rare alleles in a population, a pattern observed with the CARD15 IBD risk alleles that are less 
common but have strong effects on disease risk.50 Regardless of the genetic model that can explain these effects, 
it is clear that determining the functional consequences of these effects and mechanistic link to disease will 
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Table 4: Replication study results - follow-up of the TLR pathway screen 
Phenotype Putative risk allele or 
haplotype 
 Replication data  Association with IBD (P-value) 














3 to -5) 
All tested 
samples P- 
value and odds 
ratio  
(95% CI) 
IBD IRAK2-H.B.1: GA    0.042 0.954 0.783 
 T:U  20:30 187:215   0.93 (0.81-1.06) 
 Frequency cases 14.4      
 Frequency controls 15.1      
 IRAK2-H.B.2: GTA    0.017 0.751 0.488 
 T:U  27:27 288:306   1.00 (0.89-1.213) 
 Frequency cases 18.5      
 Frequency controls 18.8      
IBD TIRAP-rs671492-G    0.033 0.032 0.007 
 T:U  36:39 341:295   1.15 (1.03-1.28) 
 Frequency cases 76.5      
 Frequency controls 74.1      
IBD TLR3-H.B.1: CT    0.037 0.463 0.207 
 T:U  41:43 375:407   0.96 (0.86-1.07) 
 Frequency cases 71.0      
 Frequency controls 69.4      
IBD TLR4-H.B.1: GCC    0.045 0.887 0.622 
 T:U  37:41 358:382   0.97 (0.88-1.08) 
 Frequency cases 26.5      
 Frequency controls 27.9      
Abbreviations: CI, confidence interval; IBD, inflammatory bowel diseases; NIDDK, National Institute of Diabetes and Digestive and 
Kidney; T:U, transmitted:untransmitted. The frequencies reported in the table are derived either from healthy control subjects (Canada and 
Belgium columns) or from parents (NIDDK column). In the case of Belgian and Canadian samples, there was no significant difference in 
allele frequencies between healthy control subjects and subjects who are parents of a trio (data not shown). The results deemed to be 
statistically suggestive are highlighted in bold. 
 
Materials and methods 
Subjects 
All affected subjects fulfill clinical criteria for IBD51,52 and were consented using protocols approved by the 
Institutional Review Boards of each institution contributing samples. All DNA samples were extracted from the 
blood of the consented subjects. The complete collection assembled for this study consists of 1919 subjects with 
IBD. In most cases, a clinical subtype of CD or UC was assigned using standard clinical criteria;51 few cases 
were deemed to be cases of 'indeterminate colitis' and were not used in the CD- or UC-only analyses. In total, 
five different collections (IBD-1 to -5) were used in the analysis (Table 1). Collections IBD-1 and -2 were 
collected at multiple sites in the province of Quebec, Canada; these subjects are all of European ancestry. In the 
IBD-2 collection, self-declared healthy control subjects were matched to cases on the basis of ethnicity53 
Collection IBD-3 is described below. Collection IBD-4 consists of Belgian subjects of European ancestry 
collected at the Erasme Hospital, Brussels. Collection IBD-5 was established by the National Institute of 
Diabetes and Digestive and Kidney (NIDDK) Diseases IBD Genetics Consortium and consists of samples from 
several different collections from the United States and Canada. Out of 933 trios in collection IBD-5, the vast 
majority of probands are of European ancestry; there were 17 probands of Asian ancestry, four African-
American probands, five probands with 'other' ancestry and six of unknown ancestry. For the phenotypic 
analyses of the IBD-5 collection, we used the CD and UC phenotypes available in the 'trio pheno release 1.2' of 
the NIDDK-sponsored database. The clinical features of this sample collection has recently been published.54 Of 
note, sample collection 'IBD-3' consists of samples from four independent collections. Collection 1 from the 
Erasme Hospital, Brussels, Belgium: 179 subjects affected with CD.24 Collection 2 from the University of Liege, 
Belgium: 429 subjects affected with IBD and 96 healthy control individuals.55 Collection 3 from the University 
of Leuven, Belgium: 191 healthy control individuals collected as controls for another IBD study56 Collection 4 
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from University of Leuven, Belgium: 192 healthy control individuals collected to serve as a control population 
for a multiple sclerosis project.57 All affected and control subjects were collected within a 100 km radius and are 
all of European ancestry. Because of the disparate origins of its component sample collection, the pooled 
collection of cases and controls from Belgium is not precisely matched. It should be viewed as a pooled 
collection of subjects with IBD and unrelated individuals collected from the same population. To assess for the 
possibility of population stratification, allele frequencies in the three different healthy control samples 
(collections 2-4) were compared, and marginal heterogeneity was noted at only 1 (rs4986790) out of 24 SNPs 
genotyped between collection 1 and 4 (χ2 test: P = 0.043). Allele frequencies between the affected subjects from 
collection 1 and 2 showed no evidence of genetic heterogeneity. As a result, there is no strong evidence for 
population stratification among the control subjects and cases; all cases and all controls from these four 
collections were pooled for our analyses; the marginal heterogeneity at rs4986790 in control subjects is noted 
and is taken into account in our interpretation of results regarding this SNP. 
Study design: TLR pathway screen 
This part of the study consists of a screening phase and a replication phase to evaluate alleles and haplotypes of 
the genes of interest. At the initiation of this study the haplotype data from the International HapMap project 
were not yet available, and therefore we genotyped 86 Canadian subject-parent trios to characterize the LD 
patterns surrounding these genes to identify tag SNPs. 
Specifically we searched the UCSC Genome Browser and dbSNP for SNPs providing a target SNP density of 1 
SNP every 2.5 kb in the selected genomic segments. For each of the 23 genes studied, we selected SNPs between 
the transcription initiation site and the end of the 3' untranslated region (genic region) as well as in at least 20 kb 
of flanking sequence upstream and 20 kb of flanking sequence downstream of the genic region. SNP selection 
for this study took place in 2002, before the availability of the Haplotype Map, and many of the SNPs that we 
selected based on our coverage goal of 1 SNP/2.5 kb were either not polymorphic or genotyped poorly in the 
subset of our screening sample used for SNP validation. In all, we genotyped this validation sample of 86 
Canadian IBD trios with 379 SNPs from 22 peri- and intragenic areas totaling 694 kb. The initial study-wide 
SNP density was therefore 1 SNP every 1.8 kb 17 genes yielded at least two SNPs that passed our quality control 
parameters (see Genotyping section) and were screened in the screening phase. Despite two rounds of SNP 
testing, no useful SNP could be found at the completion of validation efforts in four genes: IKBKG, IRAK1, 
MYD88 and TLR7. TAB2 and TLR8 each yielded a single usable SNP. These six genes were therefore not 
studied further. Overall, 115 SNPs in 17 genes were characterized as tag SNPs. 
In the association screen of this biological pathway, we typed the 115 tagging SNPs in the entire set of Canadian 
collections of affected subject/parent trios (collection IBD-1) and matched case and control subjects (collection 
IBD-2; Table 1). Given the size of our sample set for the screening phase, the SNPs and haplotypes tested in our 
analysis were limited to those found at a frequency >0.l in the healthy Canadian population. To illustrate this 
point, we estimate that we have 80% power to detect an allele associated with an OR of 1.7 for IBD and found at 
a frequency of 0.1 in our screening sample given a multiplicative model of disease and an α = 0.05 as a threshold 
for replication. Thus, our statistical power to explore the role of rarer SNPs and haplotypes is limited, and we did 
not pursue their assessment as part of this study. A combined Z-score and P-value were calculated as described 
in the Statistical Analysis section for each SNP and haplotype, which had a frequency >0.1 in the IBD-1 and -2 
populations (Table 2). We considered all SNPs or haplotypes, of at least 10% frequency and having a combined 
two-tailed nominal P<0.05 for association to IBD as being putatively associated. 
We tested all putatively associated SNPs and haplotypes in an independent replication study. Specifically, the 
relevant SNPs were typed in the combined replication panel that consists of three different sample collections: 
IBD-3 to -5 (Table 1). A combined Z-score is calculated as described in the Statistical Analysis section, and the 
resulting one-tailed P-value is the primary outcome of the replication effort. To be considered replicated, a 
hypothesis tested in the replication cohort must have a P<0.01, which is derived from an α = 0.05 with 
Bonferroni correction for testing five hypotheses. 
Genotyping 
All samples were genotyped using the Sequenom MassArray system as described previously53 All genotypes on 
collections IBD-1 to -5 were generated by the genotyping center of the Whitehead Institute Center for Genome 
Research (now called the Broad Institute). We used data only from those SNPs that showed >90% genotyping 
success, did not deviate from Hardy-Weinberg equilibrium (P> 0.001) in the control subjects, and had one or 
fewer Mendelian error in each trio collection (IBD-1 to -5). 
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Figure 1: Haplotype structure of TLR4. This diagram illustrates the haplotype structure of the genomic segment 
investigated during our study. It was created using the LocusView software. The genomic segment of interest is outlined in black in 
the middle of the figure, and its physical boundaries are noted in megabases (Mb). Human genome assembly 16 (hg16) is the reference 
selected for these physical positions. Above the genomic segment, the position of the TLR4 gene is noted in pink and blue. Below the 
genomic segment, each of the thirteen SNPs used in the study is listed, and its position is indicated. Below the SNPs, the various haplotypes 
with >0.0l frequency in our subject sample IBD-1 (Canadian trios) are noted. Each haplotype is found within a gray box with its component 
alleles; the haplotype frequency is noted within each box and is also demonstrated visually by the blue bar. The thickness of the blue bar is 
directly proportional to the frequency of the haplotype. The SNPs are listed again below the haplotype portion of the diagram and serve as 
reference points for the demonstration of pairwise linkage disequilibrium; the color scheme is illustrated below; the intensity of the red color 
being proportional to the extent of D'. 
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Determining haplotypes 
Many different protocols can be used to define boundaries of blocks of LD. We used the 'solid spine of LD' 
definition available in the Haploview program as the standard for this study58 This definition allows for certain 
intervening polymorphisms not to be in LD with each other as long as the first and last markers are in strong LD 
with each other. The algorithm embedded in Haploview constructs multimarker haplotypes using the expectation 
maximization statistical algorithm59 modified to process large data sets using the partition-ligation approach.60 
hg17 is used as the reference for all SNP positions. 
Statistical analyses 
Association testing. Genetic association was assessed by the transmission disequilibrium test for collections 
consisting of trios.61 Association in cases and controls was determined by a standard χ2 test done on a 2 x 2 
contingency table. In both cases, the Haploview program was used as the primary analytical platform to 
implement these tests.58 
Combining analyses.  
For the primary outcome of the study, the results of each sample collection were produced independently and 
combined by calculating a Z-score and subsequently a P-value. Specifically, the number of risk alleles 
transmitted in trios or found in cases and controls was reformatted as a mean or expected count (ET and Ec), 
observed count (OT and Oc), and variance (varT and varc). A combined Z-score was then calculated by 
summation as Z = [(OT + Oc)-(ET + Ec)]/√ (varT + varc). Collections IBD-1 and -2 were combined in the 
screening phase of the study, and a two-tailed P-value was calculated from the combined Z-score. Collections 
IBD-3 to -5 were combined in the replication phase; as only the over-representation of a single allele or 
haplotype (based on the phase 1 results) is studied in the replication phase of the study, a one-tailed P-value was 
calculated for the replication Z-score. 
Pooled analysis 
We combined data from our study and from each relevant published study by calculating a Z-score as described 
in the preceding section. Since these pooled analyses are testing a single hypothesis (that a specific allele is 
associated with disease susceptibility), a one-tailed P-value was calculated from this Z-score to assess the 
statistical significance of the analysis. A Mantel-Haenszel approach was used to calculate a pooled OR.36 
Assessing heterogeneity.  
A Pearson χ2 goodness-of-fit test to assess the level of genetic heterogeneity among sample populations was 
applied to both the study's data and data used in the pooled analyses as described previously62 
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